Trial Profile
A Non-Controlled, Open-Label, Multicenter, Study of Immune Tolerance Induction Performed With rFVIIIFc Within a Timeframe of 60 Weeks in Severe Haemophilia A Patients With Inhibitors Who Have Failed Previous Immune Tolerance Induction Therapies
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Dec 2021
Price :
$35
*
At a glance
- Drugs Efmoroctocog alfa (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Acronyms ReITIrate
- Sponsors Swedish Orphan Biovitrum
- 06 Jul 2021 According to a Swedish Orphan Biovitrum media release, final results from the study will be presented at the virtual ISTH 2021, the 29th Congress of the International Society on Thrombosis and Haemostasis.
- 04 Sep 2020 Status changed from active, no longer recruiting to completed.
- 22 Feb 2020 According to European Clinical Trials Database record, trial is completed in Slovenia.